| Literature DB >> 28405442 |
Anna Pérez-Bosque1, Javier Polo2, David Torrallardona3.
Abstract
The use of growth promoting and therapeutic antibiotics in piglet feed has been a concerning subject over the last few decades because of the risk of generating antimicrobial resistance that could be transferred to humans. As a result, many products have been proposed as potential alternatives to the use of antibiotics, and among these, spray dried plasma is considered one of the most promising. However, there have been concerns about its biosafety, particularly during periods of emergence or re-emergence of swine diseases in different regions of the world, such as the recent porcine epidemic diarrhea virus outbreak in North America. The objectives of this paper are to review recent publications about the use of spray dried plasma as an alternative to antibiotics in weaned pig diets, the possible mechanisms of action of spray dried plasma, and the existing evidence related to the biosafety of spray dried animal plasma. Particular attention is given to studies in which spray dried plasma has been directly compared to antibiotics or other alternative antimicrobial products. Several studies on the possible modes of action for spray dried plasma, such as preservation of gut barrier function or modulation of the immune response, are also reviewed. Finally, the paper focuses on the review of the existing studies on the risks of disease transmission with the use of spray dried plasma from porcine origin. Overall, spray dried plasma is a promising alternative to in-feed antimicrobials for piglets, particularly during the early stages of the post-weaning phase. Additionally, there is enough evidence to support that commercial spray dried porcine plasma is a safe product for pigs.Entities:
Keywords: Antibiotic replacement; Antibiotics; Biosafety; Gut barrier function; Immunomodulation; Piglets; Spray dried plasma; Spray dried porcine plasma
Year: 2016 PMID: 28405442 PMCID: PMC5382520 DOI: 10.1186/s40813-016-0034-1
Source DB: PubMed Journal: Porcine Health Manag ISSN: 2055-5660
Fig. 1Schematic overview of general steps involved in the industrial production of spray-dried plasma. Critical control points for quality assurance and quality control. Manufacturers following good manufacturing practices collect blood from animals inspected and determined fit for slaughter for human consumption. Blood flows into an enclosed system, separated into plasma and blood cell fractions, rapidly chilled to 4 °C and held in insulated holding tanks. Then plasma is transported in cleaned, sealed dedicated tankers to a remote spray drying facility where it is held in insulated tanks. Alternatively, the whole blood is chilled to 4 °C in the slaughterhouse and transported to remote spray drying facility where it is split into plasma and blood cells fractions. At abattoirs, collection systems and holding tanks are cleaned and sanitized by standard operating procedures specific for each plant. Holding tanks at abattoirs or spray drying plants are cleaned and sanitized when emptied. Filtration and concentration systems are cleaned per standard operating procedures. Standard operating procedures are in place for continual monitoring and recording of computer controlled spray drying process. Each lot of spray dried product is identified at packaging and must pass quality control and assurance testing before release for sale. Product lot number allows traceability of distribution to customers
Studies comparing spray dried plasma (SDP) to antibiotics or other alternative substances
| Age of piglets (days) | Challenge | SDP dose (g/kg) | Observations for SDP vs. Controla | Reference Product(s) and dose (g/kg) | Observations for SDP vs. Reference Productb | Reference |
|---|---|---|---|---|---|---|
| 21 | Uncleaned nursery | 30 | No differences observed | Egg yolk antibodies (2) | No differences observed | [ |
| 60 | ↑Weight gain | ↑Weight gain | ||||
| 21 | None | 50 | ↑Weight gain; ↑Gain:Feed ratio | Colistin (0.12) + Lincomycin (0.044) + Spectinomycin (0.044) | No differences observed | [ |
| 18 | None | 60 | ↑Weight gain; ↑Feed intake | Copper sulfate (0.2) | No differences observed | [ |
| 21 | E. coli K99 | 60 | ↑Weight Gain | Colistin (0.3) | No differences observed | [ |
| Calcium formate (18) | ↑Weight gain; ↑Feed intake | |||||
| 21 | E. coli K99 | 60 | No differences observed | Colistin (0.3) | ↑Villi height; ↑E. coli | [ |
| Calcium formate (18) | ↑Villi height | |||||
| 20 | None | 60 | ↑Gain:Feed ratio; ↓Monocytes; ↓Macrophages in Peyer’s patches; ↓Macrophages, B Lymphocytes and γδ + T cells in lymph nodes; ↓Lymphocyte and cell density in lamina propria | Carvacrol (0.015) + Cinnamaldehyde (0.009) + Capsicum oleoresin (0.006) | ↓Macrophages in Peyer’s patches; ↓Macrophages and γδ + T cells in lymph nodes; ↓Lymphocyte and cell density in lamina propria | [ |
| 21 | E. coli K99 | 60 | ↑Weight gain; ↑Gain:Feed ratio | Colistin (0.3) | No differences observed | [ |
| 26 | None | 40 | ↑Weight gain; ↑Feed intake; ↑Gain:Feed ratio | Avilamycine (0.04) | ↑Weight gain; ↑Feed intake; ↑Gain:Feed ratio | [ |
| 21 | E. coli K88 | 60 | ↑Feed intake; ↑Weight gain; ↓Specific K88 IgA; ↑Crypt depth; ↓IL-8; ↓TNF-α | Colistin (0.25) + Amoxycycline (0.5) | ↑Feed intake; ↑Weight gain; ↑Crypt depth; ↓IL-8; ↓TNF-α; ↓IFN-γ | [ |
| 10 | E. coli K88 | 50 | ↑Weight gain; ↓Scours; ↓Mortality; ↑Villi height | E. coli K88 specific egg yolk antibodies (5) | ↓Villi height | [ |
| 100 | ↑ Weight gain; ↓Scours; ↓Mortality; ↑Villi height; ↓Plasma urea N | ↓Mortality; ↓Villi height | ||||
| 10 | E. coli K88 | 100 | ↓Plasma urea N; ↓Scours; ↓Mortality; ↓E. coli K88 shedding; ↑Villi height; ↑Villi:Crypt ratio | Carbadox (0.055) | No differences observed | [ |
| E. coli K88 specific egg yolk antibodies (5) | No differences observed | |||||
| Zinc oxide (2.88) | ↑Villi height; ↑Villi:Crypt ratio | |||||
| Fumaric acid (0.02) | No differences observed | |||||
| 24 | E. coli K99 | 70 | ↑Weight gain; ↑Gain:Feed ratio; ↑Lactobacilli | Colistin (0.3) | ↑E. coli | [ |
| 21 | None | 50 | ↑Weight gain; ↑Gain:Feed ratio | Colistin (0.15) | No differences observed | [ |
| 22 & 32 | None | 50 | ↑Gain:Feed ratio | Colistin (0.15) | No differences observed | [ |
| 30 | None | 50 | ↑Weight gain; ↑Feed intake | Chlortetracycline (0.11) + Sulfamethazine (0.11) + Penicillin (0.055) + Copper sulfate (0.25) | No differences observed | [ |
aPerformance and health observations in studies comparing the effects of feeding spray dried plasma (SDP) versus a control diet without antimicrobial products
bPerformance and health observations in studies comparing the effects of feeding spray dried plasma (SDP) versus the use of antibiotics or other alternative substances
Fig. 2Representative images of the immunohistocheminal localization of activated lymphocytes in the jejunum of the Control (a), SEB (b) and SEB-SDP (c) rats. Jejunum mucosa sections were immunostained with anti-IL-2R (anti-CD25) and counterstained with Hoechst 33258 (nuclear marker). Staining for lymphocyte markers is shown in red and nuclei in green
Fig. 3Diagram summarizing the mode of action of spray-dried plasma (SDP). Food antigens and products from commensal bacteria can enter into the intestinal lamina propria across M cells (in Peyer’s patches), by dendritic cells (DC), or by paracellular pathway. This results in activation of the Gut-Associated Lymphoid Tissue (GALT), which induces an inflammatory response that can alter different intestinal functions such as intestinal barrier or nutrient absorption. GALT is interconnected to other mucosal surfaces like the Broncoalveolar-Associated Lymphoid Tissue (BALT) or the Genito Urinary-Associated Lymphoid Tissue (GUALT) by the common mucosal immune system (CMIS). Plasma supplementation can modulate the immune response at the luminal level (e.g.: modifying the microbiota profile, reducing antigen and pathogen concentration by luminal binding). Moreover, biologically active compounds present in plasma supplements can also interact directly with mucosal immune cells. The plasma-induced changes in mucosal cytokine profile can prevent or reverse deleterious effects resulting from immune system activation